Ascletis Pharma (SEHK:1672) Is Up 9.9% After FDA Clears ASC30 Phase II Diabetes Trial - What's Changed

Simply Wall St.01-09

Ascletis Pharma announced that it received U.S. FDA Investigational New Drug clearance for a 13-week Phase II trial of its oral small-molecule GLP-1 candidate ASC30 in type 2 diabetes, with enrollment...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602732510?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-09 12:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602732510","market":"us","top_or_hot":-1,"title":"Ascletis Pharma (SEHK:1672) Is Up 9.9% After FDA Clears ASC30 Phase II Diabetes Trial - What's Changed","media":"Simply Wall St.","content":"<div>\n<p>Ascletis Pharma announced that it received U.S. FDA Investigational New Drug clearance for a 13-week Phase II trial of its oral small-molecule GLP-1 candidate ASC30 in type 2 diabetes, with enrollment...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/ascletis-pharma-sehk1672-is-up-99-after-fda-clears-asc30-pha\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis Pharma (SEHK:1672) Is Up 9.9% After FDA Clears ASC30 Phase II Diabetes Trial - What's Changed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis Pharma (SEHK:1672) Is Up 9.9% After FDA Clears ASC30 Phase II Diabetes Trial - What's Changed\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-09 12:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/ascletis-pharma-sehk1672-is-up-99-after-fda-clears-asc30-pha><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ascletis Pharma announced that it received U.S. FDA Investigational New Drug clearance for a 13-week Phase II trial of its oral small-molecule GLP-1 candidate ASC30 in type 2 diabetes, with enrollment...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/ascletis-pharma-sehk1672-is-up-99-after-fda-clears-asc30-pha\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/ascletis-pharma-sehk1672-is-up-99-after-fda-clears-asc30-pha","article_id":"2602732510","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/ascletis-pharma-sehk1672-is-up-99-after-fda-clears-asc30-pha","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602732510","pubTimestamp":1767933927,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ascletis Pharma announced that it received U.S. FDA Investigational New Drug clearance for a 13-week Phase II trial of its oral small-molecule GLP-1 candidate ASC30 in type 2 diabetes, with enrollment planned to start in the first quarter of 2026.\nThe clearance builds on prior Phase II obesity data in which ASC30 delivered dose-dependent weight loss and relatively favorable gastrointestinal tolerability, reinforcing its potential as an oral treatment option across major metabolic...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK1161":"生物科技","01672":"歌礼制药-B","BK1515":"抗疫概念"},"translate_title":"FDA批准ASC30 II期糖尿病试验后，歌礼制药(SEHK：1672)上涨9.9%-发生了什么变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1.5},"content_text":"Ascletis Pharma announced that it received U.S. FDA Investigational New Drug clearance for a 13-week Phase II trial of its oral small-molecule GLP-1 candidate ASC30 in type 2 diabetes, with enrollment planned to start in the first quarter of 2026. The clearance builds on prior Phase II obesity data in which ASC30 delivered dose-dependent weight loss and relatively favorable gastrointestinal tolerability, reinforcing its potential as an oral treatment option across major metabolic diseases. We’ll now examine how the FDA’s Phase II green light for ASC30 in type 2 diabetes shapes Ascletis Pharma’s broader investment narrative. AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementWhat Is Ascletis Pharma's Investment Narrative?To own Ascletis Pharma, you really have to believe that its metabolic and dermatology pipeline can ultimately justify a company that is still very small in revenue and consistently loss making. The FDA’s Phase II green light for ASC30 in type 2 diabetes slots neatly into that story, because it moves Ascletis from an obesity-only GLP‑1 narrative to a broader diabetes opportunity, and does so on the back of encouraging weight loss and tolerability data. In the near term, though, this is more of a sentiment and validation catalyst than a financial one, with the key upcoming inflection points still tied to ASC30 obesity data readouts, the China NDA outcome for denifanstat in acne, and progress on ASC50 and the GLP‑1/GIP co-formulation. Against this, investors have to weigh persistent losses, rich biotech valuations, and execution risk across several parallel trials. However, investors should be aware of how multiple late-stage programs could strain cash and execution capacity.\nOur comprehensive valuation report raises the possibility that Ascletis Pharma is priced higher than what may be justified by its financials.Exploring Other PerspectivesSEHK:1672 1-Year Stock Price Chart The single fair value estimate from the Simply Wall St Community sits far below current levels, underscoring how differently retail investors can view Ascletis. Set that against the fresh ASC30 diabetes IND clearance, which sharpens both the upside tied to GLP‑1 progress and the risks around ongoing losses, and it becomes clear why you may want to compare several perspectives before deciding what the recent share price swings really mean for you.Explore another fair value estimate on Ascletis Pharma - why the stock might be worth less than half the current price!Build Your Own Ascletis Pharma NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Ascletis Pharma research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.Our free Ascletis Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ascletis Pharma's overall financial health at a glance.Looking For Alternative Opportunities?Our daily scans reveal stocks with breakout potential. Don't miss this chance:Outshine the giants: these 28 early-stage AI stocks could fund your retirement.Rare earth metals are the new gold rush. Find out which 39 stocks are leading the charge.The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602732510","isCrawlerRequest":true}